EyeGate Pharmaceuticals Inc represents a commitment to advancing novel therapeutics for ocular diseases. The company focuses on developing innovative drug delivery solutions utilizing its proprietary EyeGate II Delivery System. EyeGate Pharmaceuticals is dedicated to improving patients' lives by addressing unmet medical needs in ophthalmology. With an emphasis on efficient drug delivery and potential reduced treatment burden, EyeGate Pharmaceuticals strives to offer effective and patient-friendly solutions for ocular ailments. By leveraging its expertise and technological advancements, EyeGate Pharmaceuticals aims to provide innovative treatment options that enhance the quality of life for individuals suffering from eye-related conditions.

EyeGate Pharmaceuticals Inc is primarily present in the United States.

EyeGate Pharmaceuticals Inc has achieved several significant milestones in its history. The company successfully developed innovative medical technologies, including its EyeGate® II Delivery System, which enables efficient and targeted ocular drug delivery. EyeGate Pharmaceuticals Inc also received various approvals from regulatory authorities, including the CE Mark in Europe and the Investigational Device Exemption from the FDA for clinical trials. Additionally, the company entered into strategic collaborations and partnerships to advance its product pipeline, ensuring growth and long-term success. These achievements highlight EyeGate Pharmaceuticals Inc's dedication to improving ocular drug delivery methods and its commitment to providing innovative solutions in the pharmaceutical industry.

EyeGate Pharmaceuticals Inc is a leading biopharmaceutical company specializing in developing innovative ophthalmic therapies. Founded in 1998, the company has been dedicated to improving ocular health through its advanced drug delivery platforms. EyeGate's proprietary technology, such as the EyeGate II Delivery System, offers precise and targeted drug delivery to the eye, enhancing the efficacy of therapeutic treatments. With a strong focus on ocular surface diseases, EyeGate Pharmaceuticals is committed to addressing unmet medical needs and providing patients with safe and effective eye care solutions. With cutting-edge research and a commitment to innovation, EyeGate Pharmaceuticals Inc remains a prominent player in the ophthalmic industry.

The main competitors of EyeGate Pharmaceuticals Inc in the market include companies like Ocular Therapeutix Inc, Nicox S.A, and Insmed Incorporated.

EyeGate Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

EyeGate Pharmaceuticals Inc. is a biopharmaceutical company with a unique business model focused on the development and commercialization of innovative therapeutics for ocular diseases. The company specializes in developing drug delivery platforms that utilize its proprietary iontophoretic drug delivery system. This technology aims to enhance the delivery of therapeutics to the eye, potentially improving treatment efficacy and patient outcomes. EyeGate's goal is to provide novel and cost-effective solutions for various ocular conditions, including dry eye disease, allergic conjunctivitis, and post-surgical inflammation. By leveraging its expertise in ocular drug delivery, EyeGate Pharmaceuticals Inc. strives to address unmet needs and improve patients' quality of life.

De EyeGate Pharmaceuticals K/W is -18,54.

De EyeGate Pharmaceuticals KUV is 53,90.

De AlleAktien Kwaliteitsscore voor EyeGate Pharmaceuticals is 1/10.

De verwachte EyeGate Pharmaceuticals omzet is 3,05 mln. USD.

De verwachte EyeGate Pharmaceuticals winst is -8,87 mln. USD.

EyeGate Pharmaceuticals Inc is a company specializing in the development of specialized eye medications and medical devices. The company was founded in 1998 and is headquartered in Waltham, Massachusetts. The company's goal is to develop innovative solutions to cure eye diseases and improve patients' vision. In general, EyeGate Pharmaceuticals Inc's business model consists of three areas. Firstly, the company develops medications for the treatment of eye diseases. These include pharmaceutical agents such as EGP-437, which are used to treat inflammation and pain. In addition, the company has also developed an innovative delivery system that allows medications to be administered directly into the eye. Another important area of EyeGate Pharmaceuticals Inc is the development of medical devices. This includes the EyeGate II Delivery System, a device for administering medications into the eye using electromagnetic waves. The system is used to transport medications to the site of the disease and thus achieve higher effectiveness. The third area of EyeGate Pharmaceuticals Inc's business model is the conduct of clinical trials. In order to evaluate the effectiveness and safety of their medications and devices, the company conducts clinical trials. In doing so, the company collaborates closely with leading ophthalmologists and research institutions. In addition to EGP-437 and the EyeGate II Delivery System, EyeGate Pharmaceuticals Inc's products also include Ocular Bandage Gel (OBG), a hydrogel bandage for the treatment of eye diseases. The OBG is used to protect the eye without impairing the patient's vision. The product is approved in the United States and is currently marketed in Europe. EyeGate Pharmaceuticals Inc's business model is based on the development of innovative solutions for the treatment of eye diseases. The company works closely with ophthalmologists and research institutions to develop new agents and delivery systems and test them in clinical trials. Through close collaboration with medical experts, the company can quickly respond to the needs of patients and offer innovative solutions to improve patients' vision and quality of life. Overall, EyeGate Pharmaceuticals Inc relies on a wide range of products and works closely with external partners to develop new solutions for the treatment of eye diseases. The company aims to become a leader in the market of ophthalmology and offer innovative solutions to improve patients' vision.

EyeGate Pharmaceuticals keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor EyeGate Pharmaceuticals of het bedrijf keert geen dividend uit.

De ISIN van EyeGate Pharmaceuticals is US30233M5031.

Het WKN van EyeGate Pharmaceuticals is A2PRBT.

De ticker van EyeGate Pharmaceuticals is EYEG.

Binnen de laatste 12 maanden betaalde EyeGate Pharmaceuticals een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal EyeGate Pharmaceuticals naar verwachting een dividend van 0,09 USD betalen.

De dividendrendement van EyeGate Pharmaceuticals is momenteel .

EyeGate Pharmaceuticals betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden mei, juni, juli, augustus.

EyeGate Pharmaceuticals betaalde de afgelopen 2 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0,09 USD verwacht. Dit komt overeen met een dividendrendement van 0,25 %.

EyeGate Pharmaceuticals wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van EyeGate Pharmaceuticals van 5-7-2024 ter hoogte van 0,15 USD te ontvangen, moest je het aandeel voor de ex-datum op 1-7-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 5-7-2024.

In het jaar 2023 heeft EyeGate Pharmaceuticals 0 USD aan dividenden uitgekeerd.

De dividenden van EyeGate Pharmaceuticals worden in USD uitgekeerd.